Viking Therapeutics, Inc

VKTXNASDAQ • USD
ThemeBiotech - Drug Development›Metabolic & Cardiometabolic
38.04 USD
↗ 1.05 (2.84%)AT CLOSE (11:59 AM EDT)
37.87
↘ 0.17 (0.44%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
37.87
↘ 0.17 (0.44%)
🔴Market: CLOSED

Shares of Viking Therapeutics, Inc (VKTX) are trading at $38.04. There is a divergence between signals — technical indicators rate "Strong Buy" but underlying fundamentals lean "Sell". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.

Technical & fundamental data as of Jun 26, 2026.

Open?$36.36
High?$38.48
Low?$36.13
Prev. Close?$36.99
Volume?3.8M
Avg. Volume?2.4M
VWAP?$37.72
Rel. Volume?1.56x
Bid / Ask
Bid?$37.80 × 100
Ask?$38.00 × 100
Spread?$0.20
Midpoint?$37.90
Valuation & Ratios
Market Cap?4.4B
Shares Out?116.1M
Float?111.5M
Float %?96.1%
P/E Ratio?N/A
P/B Ratio?8.80
EPS?-$4.07
Dividend?0.00%
Ex-Dividend?N/A
RelatedLLYMDGLPFE
News
Profile
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Themes
Biotech - Drug Development›Metabolic & Cardiometabolic
Employees
59
Market Cap
4.3B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.vikingtherapeutics.com
Listed
2015-04-29
Address
9920 PACIFIC HEIGHTS BLVD, SUITE 350
SAN DIEGO, CA 92121
Phone: 858-704-4660
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
23
Short Sent.?
39
Piotroski F-Score?0/9Weak
Altman Z-Score?20.87Safe
Confidence?49%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?20.91%Squeeze Risk
Short Interest?23.3M
Days to Cover?11.6
Free Float111.5M
Avg Daily Volume2.0M
Settlement Date2026-06-15
Financial Health
Current Ratio?5.72Strong
Quick Ratio?5.72Strong
Cash Ratio?1.11Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 3 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
75
S&P
21
8.80HIGH▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
97
-8.6CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
Peers
33
S&P
3
-94.1%WEAK▾
ROA?
Peers
33
S&P
3
-77.7%WEAK▾
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$4.3B
Fundamentals ratios updated end of day
MarketsMoversWatchlist